Physician profile
David Haden
NPI 1316989718
$7,569.76
in general payments reported to CMS, 2019-2025
26 companies · $895 in 2025
The $895 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $1,395 · 2021: $1,150 · 2022: $1,156 · 2023: $750 · 2024: $1,138 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,697.04 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,504.39 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,439.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $921.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $548.80 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $475.66 | 2019-2025 | |
| Gilead Sciences, INC. | $147.25 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.64 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.07 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $80.91 | 2021 | |
| Merck Sharp & Dohme LLC | $61.10 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $54.34 | 2021-2025 | Zoryve |
| Corcept Therapeutics | $50.51 | 2025 | Korlym |
| Allergan, INC. | $44.09 | 2020 | |
| Abbvie INC. | $43.80 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $42.20 | 2022 | |
| Redhill Biopharma INC. | $34.97 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.83 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $32.04 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $27.45 | 2024 | Voquezna |
| Melinta Therapeutics, LLC | $25.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.43 | 2025 | Caplyta |
| Astellas Pharma US INC | $22.35 | 2020 | |
| Amgen INC. | $18.81 | 2024 | Repatha |
| Amarin Pharma, INC. | $18.24 | 2020 | |
| Esperion Therapeutics, INC. | $14.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Haden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.